Literature DB >> 15188458

Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.

Karolina Partheen1, Kristina Levan, Lovisa Osterberg, Khalil Helou, György Horvath.   

Abstract

Ovarian cancer is the leading cause of death among patients with gynecological cancers, but the biology of these tumors is still among the least understood of all major human malignancies. In this study, comparative genomic hybridization was used to determine chromosomal alterations in 98 stage III serous papillary adenocarcinomas. The tumors were grouped according to survival and the main prognostic factors stage and surgical outcome. There were chromosomal imbalances that were significantly more common in tumors from patients who died than in tumors from patients who survived: gains of 1q24-qter and losses of 4p, 4q31.1-qter, 5q12-q22, 8p, 16q, and X. Furthermore, we observed that gains of 8q23-8q24.2 and losses of 4p, 4q13-4q26, 4q31.1-qter, 5q12-q22, 8p, and 16q were significantly more common in tumors from patients with macroscopic residual tumor after primary surgery, compared to tumors from those who had undergone radical surgery. Gains of 3q13.3-qter, 6p, 7q21-q31, and 11q13-q23 and losses of 4q31.1-qter and 16q were more common in stage IIIc tumors than in stage IIIa+b tumors. On the basis of our results, we suggest that there are biological differences among the groups mentioned above and that absence of chromosomal aberrations in specific regions predicts a good clinical outcome for individual patients. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15188458     DOI: 10.1002/gcc.20053

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

Review 1.  Chromosome 6p amplification and cancer progression.

Authors:  Gda C Santos; M Zielenska; M Prasad; J A Squire
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

2.  Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.

Authors:  Jennifer A Byrne; Yuyan Chen; Nancy Martin La Rotta; Gregory B Peters
Journal:  Genes Cancer       Date:  2012-02

3.  [Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].

Authors:  A Staebler; J Diebold
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

4.  Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

Authors:  Kylie L Gorringe; Joshy George; Michael S Anglesio; Manasa Ramakrishna; Dariush Etemadmoghadam; Prue Cowin; Anita Sridhar; Louise H Williams; Samantha E Boyle; Nozomu Yanaihara; Aikou Okamoto; Mitsuyoshi Urashima; Gordon K Smyth; Ian G Campbell; David D L Bowtell
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

5.  Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma.

Authors:  Deshui Jia; Ying Jing; Zhenfeng Zhang; Li Liu; Jie Ding; Fangyu Zhao; Chao Ge; Qifeng Wang; Taoyang Chen; Ming Yao; Jinjun Li; Jianren Gu; Xianghuo He
Journal:  Cell Res       Date:  2013-12-03       Impact factor: 25.617

Review 6.  Large-scale genomic analysis of ovarian carcinomas.

Authors:  Kylie L Gorringe; Ian G Campbell
Journal:  Mol Oncol       Date:  2008-12-24       Impact factor: 6.603

7.  Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.

Authors:  T Michael Numnum; Sharmila Makhija; Baogen Lu; Minghui Wang; Angel Rivera; Mariam Stoff-Khalili; Ronald D Alvarez; Zeng Bian Zhu; David T Curiel
Journal:  Gynecol Oncol       Date:  2007-12-03       Impact factor: 5.482

8.  Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.

Authors:  Dariush Etemadmoghadam; Anna deFazio; Rameen Beroukhim; Craig Mermel; Joshy George; Gad Getz; Richard Tothill; Aikou Okamoto; Maria B Raeder; Paul Harnett; Stephen Lade; Lars A Akslen; Anna V Tinker; Bianca Locandro; Kathryn Alsop; Yoke-Eng Chiew; Nadia Traficante; Sian Fereday; Daryl Johnson; Stephen Fox; William Sellers; Mitsuyoshi Urashima; Helga B Salvesen; Matthew Meyerson; David Bowtell
Journal:  Clin Cancer Res       Date:  2009-02-03       Impact factor: 12.531

9.  Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Vera M Abeler; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Oncol       Date:  2009-09-15       Impact factor: 4.375

10.  Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.

Authors:  Lovisa Osterberg; Kristina Levan; Karolina Partheen; Ulla Delle; Björn Olsson; Karin Sundfeldt; György Horvath
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.